Peptide-doxorubicin conjugates specifically degraded by matrix metalloproteinases expressed from tumor

Drug Development Research

Volumn 67, Issue 5, 2006, Pages 438-447

  Lee, Gee Young ^a   Song, Ji Hye ^a   Kim, Sang Yoon ^b   Park, Kyeongsoon ^a   Byun, Youngro ^c  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Doxorubicin; Matrix metalloproteinases; Peptide drug conjugates; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GELATINASE A; GELATINASE B; GLYCINE; LEUCINE; MATRIX METALLOPROTEINASE; PEPTIDE; PROLINE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONJUGATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME DEGRADATION; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; WEIGHT REDUCTION;

EID: 33749010333     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20092     Document Type: Article

References (24)

1. Bremer C, Tung CH, Weissleder R. 2001. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743-748.
2. Charles FA, Nilsa G, Wei H, Eddy Y, Ross S, Zhihong L, Melody D, Randine D, Lisa G, Shu-Yun Z, Davette B, Amy M, Robert B, Mingzhu Z, Xiang J, Daniel H, Anne H, Susan D, Maria R, Sandya M, Bruce C, Swamy Y, Andrew S, Robert AC, Andrew C, Steve PS, George LT, Rebecca T, Pearl H, Allen O. 2005. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther 4:751-760.
3. Curran S, Murray GI. 2000. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621-1630.
4. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. 1993. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369.
5. Dorr RT, Von Hoff DD. 1994. Cancer chemotherapy handbook, 2nd ed. Connecticut: Appleton & Lange. 396p.
6. Dubowchik GM, Walker MA. 1999. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83:67-123.
7. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
8. Garnett MC. 2001. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 53:171-216.
9. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McConnick JJ, Klebe RJ. 1999. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 16:483-196.
10. Guu JA, Hsiue GH, Juang TM. 2002. Synthesis and biological properties of antitumor-active conjugates of ADR with dextran. J Biomater Sci Polym Ed 13:1135-1151.
11. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB. 2001. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48:269-274.
12. Hidalgo M, Eckhardt SG. 2001. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193.
13. Holle L, Song W, Holle E, Wei Y, Wagner T, Yu X. 2003. A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 2:93-98.
14. Kratz F, Drevs J, Bing G, Stockmar C, Scheuermann K, Lazar P, Unger C. 2001. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg Med Chem Lett 11:2001-2006.
15. Mansour AM, Drevs J, Esser N, Hamada FM, Badary QA, Unger C, Fichtner I, Kratz F. 2003. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 63:4062-4066.
16. Minko T, Kopečková P, Kopećek J. 2000. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 86:108-117.
17. Netzel-Arnett S, Sang QX, Moore WG, Navre M, Birkedal-Hansen H, Van Wart HE. 1993. Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry 32:6427-6432.
18. Nogusa H, Hamana H, Uchida N, Maekawa R, Yoshioka T. 2000. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpulluan- peptide-doxorubicin conjugates. Jpn J Cancer Res 91:1333-1338.
19. Seltzer JL, Akers KT, Weingarten H, Grant GA, McCourt DW, Eisen AZ. 1990. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J Biol Chem 265:20409-20413.
20. Senter PD, Springer CJ. 2001. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 53:247-264.
21. Stamenkovic I. 2000. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-433.
22. Stearns ME, Wang M. 1993. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissues. Cancer Res 53:878-883.
23. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. 1997. Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75.
24. Xia T, Akers K, Eisen AZ, Seltzer JL. 1996. Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. Biochim Biophys Acta 1293:259-266.